Multiple myeloma and secondary plasma cell leukemia

Area of Science:

• Hematology
• Oncology

Background:

• Plasma cell leukemia (PCL) is a rare and aggressive hematologic malignancy.
• It is characterized by the proliferation of malignant plasma cells in the peripheral blood and bone marrow.
• PCL can occur primarily or secondary to multiple myeloma (MM).

Observation:

• A case of a 53-year-old Brazilian woman with multiple myeloma is presented.
• Bone marrow evaluation showed 25% plasma cells, with immunohistochemistry confirming myeloma and PCL features.
• Peripheral blood smears revealed 23% circulating plasma cells, with lambda light chain expression, absence of CD56, and presence of CD20.

Findings:

• The patient was diagnosed with plasma cell leukemia.
• Treatment involved a combination of dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide.
• The patient achieved significant clinical improvement and is awaiting a bone marrow transplant.

Implications:

• This case underscores the importance of accurate diagnosis of plasma cell leukemia, even when secondary to multiple myeloma.
• The presented therapeutic approach shows potential efficacy in managing this aggressive condition.
• Further research into optimal treatment strategies for plasma cell leukemia is warranted to improve patient outcomes.